We performed high-throughput cDNA sequencing in colorectal adenocarcinoma and matching normal colorectal epithelium. All six hundred three genes in the UCSC database that were expressed in colon cancers and contained open reading frames of 1000 nucleotides or less were selected for study (total basepairs/bp, 366,686). 304,350 of these 366,686 bp (83.0%) were amplified and sequenced successfully. Seventy-eight sequence variants present in germline (i.e. normal) as well as matching somatic (i.e. tumor) DNA were discovered, yielding a frequency of 1 variant per 3,902 bp. Fifty-one of these sequence variants were homozygous (26 synonymous, 25 non-synonymous), while 27 were heterozygous (11 synonymous, 16 non-synonymous). Cancer tissue contained only one sequence-altered allele of the gene ATP50, which was present heterozygously alongside the wild-type allele in matching normal epithelium. Despite this relatively large number of bp and genes sequenced, no somatic mutations unique to tumor were found. High-throughput cDNA sequencing is a practical approach for detecting novel sequence variations and alterations in human tumors, such as those of the colon.
It is widely believed that somatic as well as germline mutations play important roles in the origin and progression of colorectal cancers (
Colorectal cancer and its matching normal colonic mucosa from a patient undergoing surgical resection at the Baltimore VA Hospital after signing informed research consent was used for this study. Clinicopathological data were as follows: 75 year-old male; moderately-differentiated colorectal adenocarcinoma of the ascending colon; tumor size, 2.5 × 1.1 × 0.5 cm; TNM stage (Fifth Edition of the TNM classification of the UICC, 1997), T2N0MX, without any other malignancies. Both colorectal adenocarcinoma and normal colonic epithelium (obtained at the location within the surgically resected specimen furthest from the tumor) were cut into smaller pieces and frozen in liquid nitrogen immediately after removal. A frozen aliquot of each specimen was crushed into pieces and lysed immediately in either TRIZOL reagent (Invitrogen Corp., Carlsbad, CA,) to extract total RNA, or lysis buffer of a DNeasy Tissue kit (QIAGEN Inc., Valencia, CA) to extract DNA, according to these manufacturers’ instructions.
HeLa S3, HT29, HCT15, HCT116, LoVo, CaCo2, LS174T, LS411N, and DLD1, purchased from the American Type Culture Collection (ATCC), and KYSE30, 70, 110, 150, 220, 410, 770, 850 and OE33, obtained from Dr. Yutaka Shimada at Kyoto University in Japan (
To increase our chances of successfully amplifying and sequencing cDNAs, we restricted our study to genes that are known to be expressed in colorectal cancer cells, based on a gene expression database at the University of California, Santa Cruz (UCSC) [
Total RNA extracted from colorectal adenocarcinoma and normal colonic epithelium was reverse-transcribed using a SuperScript III First-Strand kit (Invitrogen, Carlsbad, CA), and respective cDNA pools were made. RT-PCR was performed using an AccuPrime Supermix I Kit (Invitrogen). The PCR protocol was as follows: 1 min at 96 °C followed by 35 cycles of 30 sec at 94 °C, 45 sec at 58 °C, and 1 min at 72 °C. Secondary PCR was performed on purified template from the first RT-PCR product, using the same protocol.
A BigDye Terminator v3.1 Kit (Applied Biosystems, Foster City, CA) was used for the sequencing reaction, and sequence products were read on an SCE 9610 automated 96-capillary sequencer (Spectruby BaseSpectrum v2.10 (SpectruMedix) and analyzed with Mutation Surveyor v2.2 (SoftGenetics LLC, State College, PA). Each time candidate sequence alterations were discovered in cDNA from colorectal cancer tissue, identical procedures were followed in matched normal epitheliam to confirm whether or not they represented somatic alterations. After candidate alterations were confirmed, the entire procedure was repeated separately on a fresh aliquot of cDNA from both the cancer and normal specimens in order to exclude amplification or technical errors due to two-stage PCR. Genomic DNA sequencing was also performed on heterozygous sequence variants to confirm that identical sequence alterations were present in genomic DNA.
Because the gene ATP50 was apparently mutated, raising the possibility that it was a tumor suppressor gene, we evaluated this gene for alternative inactivation via promoter hypermethylation. MSP primer sequences of ATP50 for the methylated reaction were: forward (5′-CGAGTGGGAGC-GATTTAGGAC-3′) and reverse (5′-AACGC-CAAAATTACGACACG-3′), which amplify a 94-bp product. β-actin was selected as an internal control gene, using previously published MSP primers (
MSI at each locus was determined by analyses of the length of each PCR-amplified microsatellite. MSI status was confirmed by MSI assays at five consensus loci (BAT25, BAT26, D2S123, D5S346, and D17S250) according to criteria from a National Cancer Institute workshop (
A total of 603 genes (
Seventy-eight sequence variants within 50 genes were found among the 603 genes studied (
Tumor-specific regulation of gene expression was found for NM_001697 (ATP50, Homo sapiens ATP synthase, H+ transporting, mitochondrial F1 complex, O subunit). The sequence alterations T108C (GGT to GGC, homozygous, Gly36Gly) and A218G (AAA to AAG, homozygous, Lys73Arg) were observed only in cancer-derived cDNA, while the alterations T108TC (CGT and GGC, heterozygous, 36Gly) and A218AG (AAA and AAG, heterozygous, 73Lys and 73 Arg) were observed in cDNA from normal epithelium. Surprisingly, both T108TC (CGT and GGC, heterozygous, 36Gly) and A218AG (AAA and AAG, heterozygous, 73Lys and 73 Arg), which were identical to the two alterations observed in normal cDNA, were observed in genomic DNA from both cancer and normal tissue (
One possible mechanism for monoallelic expression observed for ATP50 was DNA methylation of its promoter region. MSP showed, however, that there was no methylation of the ATP50 promoter in colorectal cancer (
There were no somatic mutations found among the 603 genes studied or within the p53 gene.
MSI assays showed that there was no microsatellite instability in genomic DNA (
In the current study, we assumed that if a mutant protein was involved in carcinogenesis or tumor progression, this mutant would be expressed and therefore detectable in tumor mRNA. i.e. we assumed that somatic mutations involved in carcinogenesis or tumor progression would be detectable by direct cDNA sequencing. By using this strategy, we avoided the need for sequencing each exon of genomic DNA, reasoning that genes which are never expressed in normal or malignant colon probably do not participate in colorectal carcinogenesis. We discovered 78 sequence variants (44 of which had been previously reported as single-nucleotide polymorphisms, but 34 of which had never been reported) among the 603 genes (304,350 bp of ORFs) studied.
Recently, Sjoblom T. et al. performed genome-wide sequencing in breast and colorectal cancers, revealing that an average of 52 mutations occurred in each colorectal cancer(
The Sjoblom team also defined “CAN-genes” (candidate cancer genes) as those that were frequently mutated in colorectal cancers, and found that 69 genes could be included in this category. Although the CAN-genes KRAS, GNAS and TP53 were studied by us, no somatic mutations were found in these genes. Furthermore, in addition to the genes mentioned above, NRAS, HRAS, p16, and p27 were included in the current study, but these genes also contained no somatic mutations. Finally, results of MSI assays revealed MS-stability (MSS), implying an absence of mutations in the major DNA mismatch repair genes (although these genes were not studied due to their long ORFs). It is possible that other molecular pathogenetic pathways were involved in this colorectal tumorigenesis, such as those containing APC, MCC, DCC, or the TGF-β cascade: these genes were also not examined in the current study due to ORF length.
Approximately 24,000,000 bp among the entire genomic DNA sequence are reported as ORFs in the UCSC database. The average density of each SNP is once per 1.9 kilobases (i.e. 1,419,190 SNPs/2.7 gigabases of human genome sequence)(
The human ATP50 gene (X83218, NM_001697), encoding a 213-amino acid ATP synthase OSCP subunit, is a key structural component of the stalk of the mitochondrial respiratory chain F1F0-ATP synthase, which is a vital element in the cellular pathway of energy conversion (
This study poses several advantages as well as limitations. Firstly, it has been reported that some synonymous mutations may influence the stability of mRNA(
Secondly, it is conceivable that we lost some gene sequence information due to extremely low expression levels. Therefore, we employed two-stage PCR to increase our chances of successful sequencing, thereby achieving a relatively high success rate of 862/1,038 reactions, or 83.0%. Possibly, this result still may have included genes that were not expressed in our particular colorectal cancer, even though we used the UCSC database to select genes that were purportedly expressed in colorectal cancers. Our sequencing success rate appears favorable when compared to genomic DNA sequencing, where 92% of genes were successfully analyzed (
Gene list
|
|
|
|
|
|
|
|---|---|---|---|---|---|
|
|
CSTB |
|
TSC22D3 |
|
PSMD7 |
|
|
RPL38 |
|
DUSP6 |
|
PSMD8 |
|
|
CKS2 |
|
EEF1B2 |
|
PSMD9 |
|
|
COX6B1 |
|
EIF1AX |
|
PSMD10 |
|
|
COX7B |
|
EIF2S1 |
|
PSPH |
|
|
COX7C |
|
EMP1 |
|
PTBP1 |
|
|
NDUFA4 |
|
EMP2 |
|
PTK9 |
|
|
NDUFB3 |
|
EMP3 |
|
PTMA |
|
|
S100A10 |
|
ENSA |
|
PTMS |
|
|
SEPW1 |
|
ERBB3 |
|
RAD1 |
|
|
SLN |
|
ERCC1 |
|
PYCR1 |
|
|
SNRPF |
|
ESD |
|
QDPR |
|
|
SRP9 |
|
EXTL2 |
|
RAB1A |
|
|
SNN |
|
FAU |
|
RAB5A |
|
|
DYNLL1 |
|
FGF3 |
|
RAB5B |
|
|
BANF1 |
|
FGF4 |
|
RAB6A |
|
|
ATP6V0E |
|
FGF9 |
|
RAB13 |
|
|
ATOX1 |
|
FGFR1 |
|
RAB27A |
|
|
GNG4 |
|
FHL1 |
|
RAB5C |
|
|
NDUFA1 |
|
FKBP1A |
|
RAC1 |
|
|
C5orf13 |
|
FKBP3 |
|
RAC2 |
|
|
GNG5 |
|
FOLR1 |
|
RAD51L3 |
|
|
HMGN2 |
|
FRG1 |
|
RALB |
|
|
COX17 |
|
FTL |
|
RAN |
|
|
SERF2 |
|
GABRG2 |
|
RAP1A |
|
|
DLEU1 |
|
GJB1 |
|
RAP1B |
|
|
MT1F |
|
GJB3 |
|
RBBP6 |
|
|
MT3 |
|
GCLM |
|
RFC3 |
|
|
S100A2 |
|
GLO1 |
|
RFC5 |
|
|
NEDD8 |
|
GML |
|
RGS3 |
|
|
CCL19 |
|
GNAS |
|
RHEB |
|
|
SHFM1 |
|
GPR35 |
|
RLBP1 |
|
|
HMGN4 |
|
GPX2 |
|
RNF4 |
|
|
BLCAP |
|
GPX3 |
|
RNF6 |
|
|
C10orf116 |
|
GRB2 |
|
RPA2 |
|
|
TP53AP1 |
|
GSTA4 |
|
RPA3 |
|
|
SCRG1 |
|
GSTM4 |
|
RPL8 |
|
|
TIMM10 |
|
GSTZ1 |
|
RPL13 |
|
|
TIMM13 |
|
GTF2A2 |
|
RPL17 |
|
|
TIMM9 |
|
GTF2E2 |
|
RPL23A |
|
|
HIG2 |
|
GUK1 |
|
RPL29 |
|
|
LOH3CR2A |
|
H1F0 |
|
RPL36AL |
|
|
SPCS1 |
|
H2AFZ |
|
RPL36A |
|
|
TMEM14A |
|
H3F3B |
|
RPLP0 |
|
|
MTCP1 |
|
HAGH |
|
MRPL12 |
|
|
C6orf123 |
|
HADHSC |
|
RPS4X |
|
|
SERP1 |
|
HBE1 |
|
RPS11 |
|
|
S100A6 |
|
HDGF |
|
RPS15A |
|
|
KIAA0125 |
|
HFE |
|
RPS16 |
|
|
ZNF706 |
|
HINT1 |
|
RPS19 |
|
|
SS18L2 |
|
HLA-DMB |
|
RPS20 |
|
|
CHCHD8 |
|
HMGB1 |
|
RPS23 |
|
|
LOC56901 |
|
HMGB2 |
|
S100A3 |
|
|
FN5 |
|
HMGN1 |
|
S100A11 |
|
|
C14orf162 |
|
HMGA1 |
|
ACACA |
|
|
CTNNBIP1 |
|
NR4A1 |
|
AES |
|
|
C6orf149 |
|
HNRPA1 |
|
SLC25A6 |
|
|
RPL41 |
|
HNRPC |
|
ATP1B1 |
|
|
PMAIP1 |
|
HNRPD |
|
ATP5D |
|
|
LSM2 |
|
HNRPH3 |
|
ATP5G3 |
|
|
MRPL34 |
|
HOXA7 |
|
ATP6V0B |
|
|
SH3BGRL3 |
|
HOXA10 |
|
BSG |
|
|
SF3B5 |
|
HOXB6 |
|
MRPL49 |
|
|
ORF1-FL49 |
|
HOXB7 |
|
CAPZA2 |
|
|
LOC84661 |
|
HOXB8 |
|
CBFB |
|
|
USMG5 |
|
HOXC4 |
|
CCND3 |
|
|
MGC4677 |
|
HOXC6 |
|
p32/CD8A |
|
|
LEAP-2 |
|
HOXC9 |
|
CD34 |
|
|
DYNLL2 |
|
HOXC11 |
|
CD59 |
|
|
ACYP2 |
|
HOXD1 |
|
CD63 |
|
|
CDC26 |
|
HPCAL1 |
|
CDC34 |
|
|
GALIG |
|
HPS1 |
|
p16/CDKN2A |
|
|
ACACA |
|
HES1 |
|
CIRBP |
|
|
ACRV1 |
|
HSPA4 |
|
CLTA |
|
|
ADM |
|
HSPB1 |
|
CSH2 |
|
|
ADORA1 |
|
DNAJC4 |
|
SLC25A10 |
|
|
ADORA2B |
|
ID1 |
|
CTSH |
|
|
ANXA8 |
|
ID2 |
|
CTSK |
|
|
ANXA5 |
|
IDH3B |
|
CTSZ |
|
|
APEX1 |
|
IDI1 |
|
CYB561 |
|
|
APOE |
|
IFI35 |
|
DUSP2 |
|
|
FAS |
|
IFNA4 |
|
PHC2 |
|
|
AQP2 |
|
IGF2 |
|
EIF5A |
|
|
AQP6 |
|
IGFBP4 |
|
ELAVL1 |
|
|
ARF3 |
|
IL1B |
|
STOM |
|
|
ARF4 |
|
IL15RA |
|
ERCC1 |
|
|
ARF6 |
|
IMPA1 |
|
FGFR1 |
|
|
RHOA |
|
IMPA2 |
|
FHL2 |
|
|
RHOB |
|
ING1 |
|
FHL3 |
|
|
RHOC |
|
INSIG1 |
|
FKBP2 |
|
|
RND3 |
|
IRF1 |
|
FOLR1 |
|
|
rho G |
|
IRF7 |
|
FRG1 |
|
|
ARHGDIA |
|
ITPA |
|
FTH1 |
|
|
ARL1 |
|
JUN |
|
FVT1 |
|
|
ARL3 |
|
CD82 |
|
BLOC1S1 |
|
|
ART1 |
|
KCNMB1 |
|
GCSH |
|
|
ASPH |
|
KRAS |
|
GMFB |
|
|
ATF1 |
|
RPSA |
|
GPX1 |
|
|
ATF3 |
|
STMN1 |
|
GPX4 |
|
|
ATP1B1 |
|
LCN2 |
|
GSTM4 |
|
|
ATP1B3 |
|
LDHA |
|
GTF2E2 |
|
|
ATP5E |
|
LGALS8 |
|
H3F3A |
|
|
ATP5F1 |
|
LIMS1 |
|
HMGB3 |
|
|
ATP5G1 |
|
LMO2 |
|
HMOX1 |
|
|
ATP5G3 |
|
LY6E |
|
HMOX2 |
|
|
ATP5J |
|
TACSTD2 |
|
HOXB6 |
|
|
ATP6V0C |
|
TM4SF1 |
|
HOXB9 |
|
|
ATP5O |
|
TACSTD1 |
|
HPRT1 |
|
|
BAD |
|
MAP4 |
|
HRAS |
|
|
CCND1 |
|
MB |
|
IDH3B |
|
|
BCL2L1 |
|
MC1R |
|
IL10RB |
|
|
BCL2L2 |
|
MCL1 |
|
FOXK2 |
|
|
BLVRB |
|
DNAJB9 |
|
ITGB4BP |
|
|
PCGF4 |
|
RAB8A |
|
LGALS8 |
|
|
BNIP3L |
|
MEST |
|
MAFG |
|
|
BOK |
|
METTL1 |
|
MGST3 |
|
|
BPHL |
|
MFAP2 |
|
MMP19 |
|
|
BRCA1 |
|
MGST1 |
|
MSX1 |
|
|
BSG |
|
MGST2 |
|
MXI1 |
|
|
BTF3 |
|
CD99 |
|
MYL6 |
|
|
BTG1 |
|
MIF |
|
PPP1R12B |
|
|
BZRP |
|
MMP19 |
|
NDUFB4 |
|
|
C1QG |
|
MPG |
|
NDUFB6 |
|
|
CA11 |
|
MPST |
|
NDUFB9 |
|
|
SLC25A20 |
|
MSRA |
|
NFKBIA |
|
|
CALM1 |
|
MTAP |
|
NPM1 |
|
|
CALM3 |
|
GADD45B |
|
PDGFA |
|
|
CALML3 |
|
(MYL4 |
|
PFN1 |
|
|
CAMLG |
|
MYL6 |
|
PPIB |
|
|
CAPNS1 |
|
MYOD1 |
|
PPP1CA |
|
|
CASP3 |
|
PPP1R12B |
|
PRNP |
|
|
CBFB |
|
NACA |
|
PRPS2 |
|
|
CCBL1 |
|
NBL1 |
|
KLK10 |
|
|
CCND2 |
|
NDUFA8 |
|
PSMA5 |
|
|
CCNG1 |
|
NDUFB10 |
|
PSMA7 |
|
|
CCNH |
|
NDUFC2 |
|
PSME1 |
|
|
CD1A |
|
NDUFS8 |
|
RAB27A |
|
|
CD3E |
|
NF2 |
|
RAB5C |
|
|
CD9 |
|
NFKBIB |
|
RAD51L3 |
|
|
CD80 |
|
NHP2L1 |
|
RAP2A |
|
|
TNFRSF8 |
|
NM23A/NME1 |
|
RBP1 |
|
|
TNFSF8 |
|
NQO2 |
|
RPL12 |
|
|
CD44 |
|
NP |
|
RPS12 |
|
|
CD47 |
|
NPM1 |
|
SAA1 |
|
|
CD53 |
|
NPPA |
|
TSPAN31 |
|
|
CD59 |
|
NRAS |
|
SAT |
|
|
CD151 |
|
YBX1 |
|
SC4MOL |
|
|
CDC2 |
|
SLC22A18AS |
|
SCML1 |
|
|
CDC2L2 |
|
CLDN11 |
|
SCN1B |
|
|
CDK2 |
|
P2RX4 |
|
SDHB |
|
|
CDK4 |
|
P2RX5 |
|
SEC13L1 |
|
|
CDKN1A |
|
PBP |
|
TRAPPC2 |
|
|
CDKN1B |
|
PAFAH1B3 |
|
SFRS2 |
|
|
CDKN2A |
|
PRDX1 |
|
SFRS8 |
|
|
CDKN2C |
|
TCF1/PCBD1 |
|
SFRS10 |
|
|
CEBPD |
|
PCDHGC3 |
|
ST6GAL1 |
|
|
CEBPG |
|
PCNA |
|
SKP1A |
|
|
CENPA |
|
PDGFA |
|
SLC25A1 |
|
|
CETN3 |
|
PDGFB |
|
SMN2 |
|
|
CFL1 |
|
SLC25A3 |
|
SNRPA |
|
|
CEACAM4 |
|
PIGC |
|
SNRPB |
|
|
CHKB |
|
PIM1 |
|
SNRPB2 |
|
|
CISH |
|
PITPNA |
|
SNRPD2 |
|
|
CKAP1 |
|
PITX1 |
|
SNRPD3 |
|
|
AP3S1 |
|
PLA2G5 |
|
SNRPN |
|
|
CLIC1 |
|
PLAUR |
|
SOD1 |
|
|
CLK2 |
|
FXYD3 |
|
SOX12 |
|
|
CLNS1A |
|
PLSCR1 |
|
SRD5A1 |
|
|
CLTB |
|
PMP22 |
|
SRM |
|
|
CNN2 |
|
PMS2L5 |
|
SRP19 |
|
|
COMT |
|
PMS2L3 |
|
SSR1 |
|
|
KLF6 |
|
PRRX1 |
|
STC1 |
|
|
OX4I1 |
|
POLR2G |
|
SULT1A2 |
|
|
CLDN4 |
|
POLR2H |
|
STX3A |
|
|
CLDN3 |
|
POLR2I |
|
STX4A |
|
|
CLDN7 |
|
PPA1 |
|
STX5A |
|
|
CRABP2 |
|
PPIA |
|
SULT1A1 |
|
|
CREB1 |
|
PPIC |
|
SULT1A3 |
|
|
CREBL2 |
|
PPM1A |
|
SURF5 |
|
|
CREM |
|
PPM1B |
|
VAMP1 |
|
|
CRK |
|
PPP1CB |
|
VAMP2 |
|
|
CRKL |
|
PPP1CC |
|
SYBL1 |
|
|
CRYZ |
|
PPP1R2 |
|
SYPL1 |
|
|
MAPK14 |
|
PPP2CA |
|
TAF9 |
|
|
CSE1L |
|
PR 53/PPP2R4 |
|
TAF11 |
|
|
CSH2 |
|
PPP3R1 |
|
TAPBP |
|
|
CSNK2A1 |
|
PRKAB2 |
|
TARBP2 |
|
|
CSNK2B |
|
PRKACB |
|
TCEA1 |
|
|
CSRP2 |
|
PRKAG1 |
|
TCF7 |
|
|
CTSK |
|
MAPK10 |
|
PRDX2 |
|
|
DAP |
|
MAP2K3 |
|
TEAD4 |
|
|
DBI |
|
PRPS1 |
|
TFAM |
|
|
GADD45A |
|
KLK7 |
|
TGIF |
|
|
DDIT3 |
|
KLK6 |
|
TIMP2 |
|
|
DDT |
|
PSG4 |
|
TSPAN6 |
|
|
DDX11 |
|
PSG11 |
|
TSPAN4 |
|
|
DFFA |
|
PSMA1 |
|
TNFAIP1 |
|
|
DHFR |
|
PSMA4 |
|
TNNI3 |
|
|
CYB5R3 |
|
PSMA6 |
|
TPD52 |
|
|
DLX4 |
|
PSMB2 |
|
TPD52L1 |
|
|
DPAGT1 |
|
PSMB10 |
|
TPD52L2 |
Sequence variants
|
|
|
||||||||
|---|---|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
|
|
QDPR Leu132Leu | G396A, | rs |
||||||
|
|
SAA1 | C209T, Ala70Val |
|
||||||
| T224C, Val75Ala |
|
||||||||
|
|
RPS4X Leu164Leu | G492A, |
|
||||||
|
|
RPS16 Gly5Gly | C15T, |
|
||||||
| T27G, Ser9Ser |
|
||||||||
|
|
SRD5A1 | A309AG, Pro103Pro |
|
||||||
| G348GA, Ala116Ala |
|
||||||||
|
|
CSNK2B Tyr46Tyr | T138C, |
|
||||||
|
|
SLC25A6 Phe136Phe | T408C, |
|
||||||
|
|
ATP50 Gly36Gly | T108C, |
|
A218AG, Lys73Arg |
|
||||
|
|
CCND3 | T775TG, Ser259Ala |
|
||||||
|
|
CEACAM4 | T668A, Val223Glu. |
|
||||||
|
|
COX4I1 | G7GA, Ala3Thr |
|
||||||
|
|
CRYZ Gly18Gly | G54A, |
|
T138C, Gly46Gly |
|
||||
|
|
HMGA1 Ser2Ser | T6C, |
|
G49A, Glu17Lys |
|
||||
| G78T, Arg26Arg |
|
G112A, Gly38Arg |
|
||||||
| C255A, Gly85Gly |
|
Pro48Leu | C143T, |
|
|||||
| C217T, Arg73Gly |
|
||||||||
| C236T, A237G, |
|
||||||||
| Pro79Leu G286A, |
|
||||||||
| Glu96Lys | |||||||||
|
|
HNRPA1 Gly248Gly | C744T, |
|
||||||
|
|
CD99 | C369CT, Ala121Ala |
|
||||||
|
|
PIGC Gly89Gly | T267C, |
|
||||||
|
|
PSMD9 | T50C, Val17Ala |
|
||||||
|
|
SSR1 | C388T, His130Tyr |
|
||||||
|
|
TIMP2 | G303GA, Ser101Ser |
|
||||||
|
|
CDKN1B | T326TG, Val109Gly |
|
||||||
|
|
KCNMB1 | G193GA, Glu65Lys |
|
||||||
|
|
SNRPD3 Ala101Ala | T303C, |
|
||||||
|
|
CETN3 | G28GC, Val10Leu |
|
||||||
|
|
FHL3 Pro180Pro | G540A, |
|
||||||
|
|
NDUFC2 | C136CG, Leu46Val |
|
||||||
|
|
ATF1 | C327CT, Tyr109Tyr |
|
||||||
|
|
CD80 | G135GA, |
|
||||||
| Val45Val | |||||||||
|
|
GPR35 | G85GA, Ala29Thr. A880AC, |
|
||||||
|
|
HMGB3 Asn186Lys | C558G, |
|
Ser294Arg | |||||
|
|
NACA | T543TA, Ile181Ile |
|
||||||
|
|
SLC25A1 Lys277Lys | A831G, |
|
||||||
|
|
HMGN4 Gly66Gly | G198A |
|
||||||
|
|
HOXA7 Ala32Ala | T96G, |
|
G52A, Ala18Thr |
|
||||
|
|
COMT His12His | C36T, |
|
G322A, Val108Met |
|
||||
|
|
BZRP His53Arg | A158G, Ala68Ala |
|
G204GA, |
|
||||
|
|
DNAJB9 Pro61Pro | G183A, |
|
||||||
|
|
HIG2 Glu28Glu | A84G, |
|
||||||
|
|
HOXC11 Ser12Ser | T36G, |
|
||||||
|
|
VAMP2 | T346A, Ser116Thr |
|
||||||
|
|
IFNA4 | A146AC, |
|
||||||
| His49Pro G178GC, |
|
||||||||
| Gly60Arg T190TA, |
|
||||||||
| Phe64Ile G187GC, |
|
||||||||
|
|
GJB3 | Glu63Gln C357CT, |
|
||||||
| Asn119Asn | |||||||||
|
|
RPL13 | G334A, Ala112Thr |
|
||||||
|
|
MGC4677 | G28T, Ala10Ser |
|
C12CT, Thr4Thr |
|
C109CT, Arg37Cys |
|
||
|
|
CDKN2A | Arg54Gly | A160T, |
|
|||||
|
|
KLK10 | A318C, Gly106Gly |
|
T347C, Leu116Pro |
|
||||
| C336G, Thr112Thr |
|
||||||||
| G423A, Leu141Leu |
|
` | |||||||
|
|
IL15RA | C248T, Pro83Leu | ` |
|
|||||
| A337C, Thr113Pro |
|
||||||||
|
|
C1QG | Gly215Glu | G644A, |
|
|||||
|
|
CREM | Ile137Thr | T410C, |
|
|||||
|
|
TEAD4 | Pro194Leu | C580CT, |
|
|||||
|
|
LGALS8 | Met56Val. | A166AG, |
|
|||||
| G542GC, Gly181Ala |
|
||||||||
No report found.
Please note that this article may not be used for commercial purposes. For further information please refer to the copyright statement at
This work was supported by NIH grants CA77057, CA95323 and CA85069 (to S.J.M.).
Sequence variants
|
|
|
|||
|---|---|---|---|---|
| Synonymous | Non-synonymous | Synonymous | Non-synonymous | |
| Number of alterations | 26 | 25 | 11 | 16 |